NYSE:ZBH - Zimmer Biomet Stock Price, News & Analysis

$138.79
-3.82 (-2.68 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$138.30
Now: $138.79
$143.5650
50-Day Range
$124.23
MA: $136.87
$139.97
52-Week Range
$96.99
Now: $138.79
$143.57
Volume1.09 million shs
Average Volume905,560 shs
Market Capitalization$28.50 billion
P/E Ratio18.17
Dividend Yield0.67%
Beta1.15
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone574-267-6131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.93 billion
Cash Flow$17.1134 per share
Book Value$55.28 per share

Profitability

Net Income$-379,200,000.00

Miscellaneous

Employees19,000
Market Cap$28.50 billion
Next Earnings Date10/25/2019 (Estimated)
OptionableOptionable

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.


Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Tuesday, September 3rd. Stockholders of record on Monday, September 30th will be given a dividend of $0.24 per share on Thursday, October 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, September 27th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) issued its quarterly earnings results on Friday, July, 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.91 by $0.02. The medical equipment provider earned $1.99 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The firm's quarterly revenue was down .9% on a year-over-year basis. During the same period last year, the firm earned $1.92 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Friday, October 25th 2019. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $7.75 -7.90 for the period, compared to the Thomson Reuters consensus estimate of $7.80. The company issued revenue guidance of $7.94 billion, compared to the consensus revenue estimate of prior $7.70-7.90.

What price target have analysts set for ZBH?

22 brokers have issued 1-year target prices for Zimmer Biomet's stock. Their predictions range from $108.00 to $167.00. On average, they expect Zimmer Biomet's stock price to reach $141.9386 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 6 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "Zimmer Biomet ended the quarter on a strong note with better-than-expected results. However, the year-over-year performance remained sluggish. The company witnessed strength in the Europe, Middle East and Africa and Asia-Pacific region as well as in the S.E.T. and Dental businesses. Zimmer Biomet is executing well within its priority areas like quality remediation, supply recovery efforts and product launches. In terms of product launch, the strong rollout of ROSA, mymobility and Persona Partial and Cementless are clearly among major achievements. Zimmer Biomet has outperformed its sector in the past six months. However, sales in Americas remained sluggish. Escalating costs and expenses are denting the adjusted operating margin for the company. Adverse currency movements continue to be a concern. Declining dental sales at CER also disappoint." (8/31/2019)
  • 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)

Has Zimmer Biomet been receiving favorable news coverage?

News stories about ZBH stock have trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zimmer Biomet earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Zimmer Biomet.

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Celgene (CELG), AT&T (T), Cisco Systems (CSCO), General Electric (GE), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Visa (V), Bristol-Myers Squibb (BMY), CVS Health (CVS) and Citigroup (C).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.00%), BlackRock Inc. (8.00%), Vanguard Group Inc. (7.53%), JPMorgan Chase & Co. (4.78%), Invesco Ltd. (3.45%) and Price T Rowe Associates Inc. MD (2.95%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Balyasny Asset Management LLC, First Trust Advisors LP, UBS Asset Management Americas Inc., Jennison Associates LLC, Jennison Associates LLC, Zurich Insurance Group Ltd FI and Bank of New York Mellon Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Didier Deltort and Sang Yi. View Insider Buying and Selling for Zimmer Biomet.

Which major investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Invesco Ltd., Boston Partners, Point72 Asset Management L.P., Prudential Financial Inc., Suvretta Capital Management LLC, Waddell & Reed Financial Inc. and D. E. Shaw & Co. Inc.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $138.79.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $28.50 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe.View Additional Information About Zimmer Biomet.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com/.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  697 (Vote Outperform)
Underperform Votes:  587 (Vote Underperform)
Total Votes:  1,284
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel